Please login to the form below

Not currently logged in
Email:
Password:

ovarian cancer

This page shows the latest ovarian cancer news and features for those working in and with pharma, biotech and healthcare.

Tecentriq misses the mark in advanced ovarian cancer

Tecentriq misses the mark in advanced ovarian cancer

The phase 3 IMagyn050 study evaluated the addition of Tecentriq (atezolizumab) to Roche’s older treatment Avastin (bevacizumab) alongside chemotherapy (paclitaxel and carboplatin) in women with advanced-stage ovarian cancer. ... Ovarian cancer remains

Latest news

  • EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

    About 5-7% of metastatic pancreatic cancers are caused by mutations in one or both BRCA genes, which are commonly associated with ovarian and breast cancer but can be seen in ... GSK’s Zejula is more of a threat to Lynparza in the ovarian cancer market,

  • AZ’s comeback drug cediranib stumbles in phase 3 trial AZ’s comeback drug cediranib stumbles in phase 3 trial

    That results led to speculation that the combination could become a chemo-free option for relapsed ovarian cancer patients. ... trial – involving patients with relapsed platinum-resistant ovarian cancer and due to generate results later this year –

  • Gilead swoops on Forty Seven with $4.9bn all-cash deal Gilead swoops on Forty Seven with $4.9bn all-cash deal

    Gilead Sciences has bulked up its oncology pipeline with a $4.9 billion all-cash deal to acquire Forth Seven, which specialises in cancer immunotherapies targeting the CD47 immune checkpoint. ... Forty Seven is also testing the drug in patients with

  • IMV preps pivotal trials for ovarian cancer T cell therapy IMV preps pivotal trials for ovarian cancer T cell therapy

    ovarian cancer, have set it on course for a registration trial. ... The Canadian biotech revealed data from the 22-patient DeCidE1 study shows that the drug stabilised disease in 79% of 19 evaluable patients with advanced, recurrent ovarian cancer, with

  • FDA accepts review to broaden GSK’s Zejula label FDA accepts review to broaden GSK’s Zejula label

    GSK is seeking approval for Zejula (niraparib) as a first-line maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of biomarker status. ... with advanced ovarian cancer who have already

More from news
Approximately 37 fully matching, plus 179 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    That includes potential new approvals for PARP inhibitor Lynparza in prostate and pancreatic cancer to extend its existing use in ovarian and breast cancer. ... in July 2019, which involved 22 plaintiffs who alleged using J&J talc caused them to develop

  • Case study: Ovarian Cancer Action (OCA) Case study: Ovarian Cancer Action (OCA)

    Every rose had a tag with the symptoms of ovarian cancer, Ovarian Cancer Action’s url and #WOCD. ... The charity also lobbied politicians across the UK to support World Ovarian Cancer Day.

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    Reic said the adoption of diagnostics into standard clinical practice has been one of the biggest challenges in Lynparza’s first indication, ovarian cancer – but this must now be replicated in ... First we had ovarian cancer, then breast cancer, and

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... People who have BRCA gene mutations have an

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    There are two stand- out good news stories for AZ in 2018 – the growth of its cancer medicines portfolio and industry-leading sales expansion in China. ... Other key launches will include Lynparza, its ovarian cancer treatment, now co-marketed globally

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics